Cryoport introduces HV3 cryogenic system for advanced therapy transport

Cryoport, Inc. has unveiled its latest innovation in temperature-controlled supply chain technology – the Cryoport Express Cryogenic HV3 Shipping System. This development addresses critical challenges in transporting temperature-sensitive biological materials, particularly for cell and gene therapies requiring consistent cryogenic conditions below minus 150°C.

Cryoport introduces HV3 cryogenic system for advanced therapy transport

Technical specifications and design features

The HV3 system incorporates several technical advances in cryogenic transport. Its rectilinear architecture eliminates traditional palletisation requirements, enabling compatibility with narrow-bodied aircraft and expanding available shipping routes. The system maintains payload integrity through enhanced temperature stability protocols whilst incorporating Cryoport’s proprietary Safepak System, utilising non-metallic materials to minimise vibration effects during cellular material transport.

Enhanced operational efficiency

Laboratory technicians and clinical staff will benefit from improved handling characteristics, including integrated wheels and front-facing handles. The system’s stackable design optimises storage efficiency at research facilities, manufacturing sites, and clinical centres. These engineering modifications reduce resource requirements at point-of-care locations whilst maintaining strict temperature control parameters.

Supply chain optimisation

The development addresses specific challenges in advanced therapy logistics. Mike Dybicz, Chief Product Development Officer at Cryoport Systems, explains: “We are passionate about providing novel solutions to meet market, user and biologic product specific transport/protection challenges and are united in our shared goal of enhancing patient access to critical, life-saving therapies.”

Regulatory compliance and monitoring

The system incorporates integrated condition and location monitoring capabilities, ensuring Chain of Compliance throughout the transport process. This feature provides continuous verification of temperature maintenance and handling conditions, critical for regulatory requirements in advanced therapy transport.

Clinical accessibility improvements

A significant advancement is the system’s ability to facilitate therapy delivery to previously underserved regions. Jerrell Shelton, CEO of Cryoport, notes: “We are improving patient access to vital cell therapies in smaller cities and remote areas, which will ultimately improve patient outcomes at large.”

Additional features include:

  • Enhanced payload protection systems
  • Dedicated storage for non-temperature sensitive accessories
  • Comprehensive documentation capabilities
  • Full airline compliance specifications
  • Integration with existing cryogenic infrastructure